Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−3.28 EUR
−147.74 M EUR
0.00 EUR
46.07 M
About ABIVAX
Sector
CEO
Marc M. P. de Garidel
Headquarters
Paris
Website
Founded
2013
ISIN
FR0012333284
FIGI
BBG009CG7F64
Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. It offers commercial and development products of anti-viral compounds and human vaccines. The commercialized products include vaccines for typhoid fever, meningococcus, and leptospirosis. The products under development include vaccines for chronic hepatitis B, ebola, and dengue virus. The company was founded by Philippe Pouletty on December 4, 2003 and is headquartered in Paris, France.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of ABVX is 9.45 EUR — it has decreased by −2.28% in the past 24 hours. Watch ABIVAX stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on EURONEXT exchange ABIVAX stocks are traded under the ticker ABVX.
ABVX stock has fallen by −0.63% compared to the previous week, the month change is a 14.27% rise, over the last year ABIVAX has showed a −2.48% decrease.
We've gathered analysts' opinions on ABIVAX future price: according to them, ABVX price has a max estimate of 44.73 EUR and a min estimate of 14.49 EUR. Watch ABVX chart and read a more detailed ABIVAX stock forecast: see what analysts think of ABIVAX and suggest that you do with its stocks.
ABVX reached its all-time high on Dec 23, 2020 with the price of 39.00 EUR, and its all-time low was 3.87 EUR and was reached on Aug 23, 2016. View more price dynamics on ABVX chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
ABVX stock is 3.87% volatile and has beta coefficient of 1.35. Track ABIVAX stock price on the chart and check out the list of the most volatile stocks — is ABIVAX there?
Today ABIVAX has the market capitalization of 611.95 M, it has decreased by −0.31% over the last week.
Yes, you can track ABIVAX financials in yearly and quarterly reports right on TradingView.
ABIVAX is going to release the next earnings report on Mar 13, 2025. Keep track of upcoming events with our Earnings Calendar.
ABVX earnings for the last half-year are −1.30 EUR per share, whereas the estimation was −1.37 EUR, resulting in a 5.34% surprise. The estimated earnings for the next half-year are −1.48 EUR per share. See more details about ABIVAX earnings.
ABIVAX revenue for the last half-year amounts to 6.80 M EUR, despite the estimated figure of 3.44 M EUR. In the next half-year revenue is expected to reach 2.95 M EUR.
ABVX net income for the last half-year is −81.64 M EUR, while the previous report showed −95.79 M EUR of net income which accounts for 14.77% change. Track more ABIVAX financial stats to get the full picture.
No, ABVX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 13, 2024, the company has 61.00 employees. See our rating of the largest employees — is ABIVAX on this list?
Like other stocks, ABVX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ABIVAX stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So ABIVAX technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating ABIVAX stock shows the sell signal. See more of ABIVAX technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.